08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
DVHA presents budget adjustment proposal - The House Health Care Committee heard from Department of...
Read More >
On November 8, 2019, OFCCP released another opinion letter clarifying the extent of its jurisdiction...
Read More >
On January 9, 2020, the U.S. Senate confirmed by voice vote both of President Donald Trump’s nomine...
Read More >
On January 7, 2020, the Department of Labor’s Wage and Hour Division (DOL) released two opinion let...
Read More >
Parties may now settle federal wage and hour claims under the Fair Labor Standards Act (FLSA) withou...
Read More >
A retirement plan participant’s failure to cash a distribution check is commonplace and gives rise ...
Read More >